Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says

The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.